ALBT

Company Overview — What Does Avalon GloboCare Corp. Do?

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey. Avalon GloboCare Corp. (ALBT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David K. Jin and employs approximately 5 people. With a market capitalization of $4M, ALBT is one of the notable companies in the Healthcare sector.

Avalon GloboCare Corp. (ALBT) Stock Rating — Avoid (April 2026)

As of April 2026, Avalon GloboCare Corp. receives a Avoid rating with a composite score of 19.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ALBT ranks #4,434 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Avalon GloboCare Corp. ranks #837 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALBT Stock Price and 52-Week Range

Avalon GloboCare Corp. (ALBT) currently trades at $0.46. The stock lost $0.03 (6.7%) in the most recent trading session. The 52-week high for ALBT is $7.89, which means the stock is currently trading -94.2% from its annual peak. The 52-week low is $0.42, putting the stock 9.5% above its annual trough. Recent trading volume was 406K shares, suggesting relatively thin trading activity.

Is ALBT Overvalued or Undervalued? — Valuation Analysis

Avalon GloboCare Corp. (ALBT) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.47x, versus the sector average of 2.75x. The price-to-sales ratio is 3.08x, compared to 1.66x for the average Healthcare stock.

At current multiples, Avalon GloboCare Corp. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Avalon GloboCare Corp. Profitability — ROE, Margins, and Quality Score

Avalon GloboCare Corp. (ALBT) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -193.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -76.4% versus the sector average of -33.1%.

On a margin basis, Avalon GloboCare Corp. reports gross margins of 505.0%, compared to 71.5% for the sector. The operating margin is -503.9% (sector: -66.1%). Net profit margin stands at -1277.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 6.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALBT Debt, Balance Sheet, and Financial Health

Avalon GloboCare Corp. has a debt-to-equity ratio of 154.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.11x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $7M. Cash and equivalents stand at $333,931.

ALBT has a beta of 0.83, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Avalon GloboCare Corp. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Avalon GloboCare Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Avalon GloboCare Corp. reported revenue of $1M and earnings per share (EPS) of $-5.64. Net income for the quarter was $-18M. Gross margin was 505.0%. Operating income came in at $-7M.

In FY 2025, Avalon GloboCare Corp. reported revenue of N/A and earnings per share (EPS) of $-5.64. Net income for the quarter was $-18M. Operating income came in at $-8M.

In Q3 2025, Avalon GloboCare Corp. reported revenue of $350,099 and earnings per share (EPS) of $-0.06. Net income for the quarter was $-254,268. Revenue grew 1.4% year-over-year compared to Q3 2024. Operating income came in at $-76,193.

In Q2 2025, Avalon GloboCare Corp. reported revenue of $350,406 and earnings per share (EPS) of $-6.22. Net income for the quarter was $-13M. Revenue grew 6.9% year-over-year compared to Q2 2024. Operating income came in at $-4M.

Over the past 8 quarters, Avalon GloboCare Corp. has demonstrated a growth trajectory, with revenue expanding from $327,887 to $1M. Investors analyzing ALBT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALBT Dividend Yield and Income Analysis

Avalon GloboCare Corp. (ALBT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALBT Momentum and Technical Analysis Profile

Avalon GloboCare Corp. (ALBT) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

ALBT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Avalon GloboCare Corp. (ALBT) ranks #837 out of 838 stocks based on the Blank Capital composite score. This places ALBT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALBT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALBT vs S&P 500 (SPY) comparison to assess how Avalon GloboCare Corp. stacks up against the broader market across all factor dimensions.

ALBT Next Earnings Date

No upcoming earnings date has been announced for Avalon GloboCare Corp. (ALBT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALBT? — Investment Thesis Summary

The quantitative profile for Avalon GloboCare Corp. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, Avalon GloboCare Corp. (ALBT) earns a Avoid rating with a composite score of 19.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALBT stock.

Related Resources for ALBT Investors

Explore more research and tools: ALBT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALBT head-to-head with peers: ALBT vs AZN, ALBT vs SLGL, ALBT vs VMD.